omniture
logo
Search
RECBIO
Media Room

Latest News

rss

Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines

TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to ann...

2022-06-27 14:47 2952

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", toge...

2022-05-05 11:55 2887

Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV

TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", t...

2022-04-13 12:56 3151

Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou

TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology ...

2022-04-11 16:05 1948

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HP...

2022-03-21 14:41 3028

Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2

TAIZHOU, China, Feb. 15, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), aChina...

2022-02-15 12:57 2752

The Philippines Has Approved ReCOV For Phase II/III Cinical Trial

* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III ...

2022-01-17 16:57 2733

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a bio...

2021-11-17 09:00 2222

Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abn...

2021-11-12 07:55 3102
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern

TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biop...

2021-11-09 10:00 2691
12